# Instil Bio’s Subsidiary Discontinues Clinical Development of AXN-2510 and Terminates License and Collaboration Agreement with ImmuneOnco
Canonical URL: https://biopharmsignal.com/news/TIL/instil-bio-s-subsidiary-discontinues-clinical-development-of-axn-2510-and-terminates-license-and-collaboration-agreement-with-immuneonco
Ticker: TIL
Company: Instil Bio
Source: Instil Bio
Published: 2026-01-06 12:00 EST
Original Source URL: https://ir.instilbio.com
## Summary

DALLAS, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (Nasdaq: TIL) (“Instil”) today announced that Axion Bio, Inc. (“Axion”), a wholly-owned subsidiary of Instil, has decided to discontinue clinical development of AXN-2510 and that Axion and ImmuneOnco Biopharmaceuticals (Shanghai) Inc.

## Article Body
DALLAS, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (Nasdaq: TIL) (“Instil”) today announced that Axion Bio, Inc. (“Axion”), a wholly-owned subsidiary of Instil, has decided to discontinue clinical development of AXN-2510 and that Axion and ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
## Recent Company News
- 2026-05-15 11:00 EST — [Instil Bio Reports First Quarter 2026 Financial Results and Provides Corporate Update](https://biopharmsignal.com/news/TIL/instil-bio-reports-first-quarter-2026-financial-results-and-provides-corporate-update) — Source: Instil Bio
- 2026-03-27 11:00 EST — [Instil Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update](https://biopharmsignal.com/news/TIL/instil-bio-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-corporate-update) — Source: Instil Bio
- 2026-01-06 12:00 EST — [Instil Bio’s Subsidiary Discontinues Clinical Development of AXN-2510 and Terminates License and Collaboration Agreement with ImmuneOnco](https://biopharmsignal.com/news/TIL/instil-bio-s-subsidiary-discontinues-clinical-development-of-axn-2510-and-terminates-license-and-collaboration-agreement-with-immuneonco) — Source: Instil Bio
- 2025-11-13 12:00 EST — [Instil Bio Reports Third Quarter 2025 Financial Results and Provides Corporate Update](https://biopharmsignal.com/news/TIL/instil-bio-reports-third-quarter-2025-financial-results-and-provides-corporate-update) — Source: Instil Bio
- 2025-09-10 11:00 EST — [Instil Bio Announces ImmuneOnco’s Presentation of ‘2510 Monotherapy Data in Patients with 2L+ Squamous NSCLC at the 2025 World Conference on Lung Cancer (WCLC)](https://biopharmsignal.com/news/TIL/instil-bio-announces-immuneonco-s-presentation-of-2510-monotherapy-data-in-patients-with-2l-squamous-nsclc-at-the-2025-world-conference-on-lung-cancer-wclc) — Source: Instil Bio
## Related News
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)
- 2026-07-29 12:25 EST — ICCM — [IceCure: SIO Petitions NCCN to Include Cryoablation in Breast Cancer Treatment Guidelines, Citing IceCure's FDA Clearance  of ProSense®](https://biopharmsignal.com/news/ICCM/icecure-sio-petitions-nccn-to-include-cryoablation-in-breast-cancer-treatment-gu-bec46cd3)